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Summary Two faecal occult blood tests, a simple chemical test Haemoccult and an immunological test,
Fecatwin Sensitive/Feca EIA, were offered to 3,225 asymptomatic individuals as screening for colorectal
cancer. One thousand three hundred and four (44%) completed and returned the tests and of these 126 (9.7%)
were found to be positive- Haemoccult 40 (3%) and Feca EIA 106 (8.1%). Five cancers (4 Dukes' Stage A,
1 Dukes' Stage C) and 23 adenomas greater than 1 cm were detected - rates of 3.8 per 1000 persons screened
and 17.7 per 1000 persons screened respectively.
Of the five cancers identified 5 were Feca EIA positive and 3 were Haemoccult positive. Of the 23
adenomas greater than 1 cm diameter identified, 11 were Feca EIA positive and 20 were Haemoccult positive.
Seventy-eight Feca EIA positive subjects were investigated and no neoplastic disease was identified. Whilst this
sensitive immunological test increases the yield of carcinomas, the high false positive rate makes it unsuitable
for population screening for colorectal cancer in its present form.
Population screening by faecal occult blood testing
has been shown to detect greater than three times
the annual incidence of colorectal cancer
(Hardcastle et al., 1983), the pathological stage of
those cancers detected by screening being more
favourable (75% Dukes' Stage A) than those in an
age/sex matched control group.
Guaiac impregnated slide tests for faecal occult
blood may produce false positive results from
reaction with either animal haemoglobin or
vegetable peroxidase (Ostrow et al., 1973; Macrae
et al., 1982), and false negative tests may result
from cancers or adenomas bleeding only
intermittently or at a level below the sensitivity of
the test (Doran & Hardcastle, 1982; Macrae & St
John, 1982). A low sensitivity test such as
Haemoccult (Eaton Laboratories) results in a low
false positive but high false negative rate (Farrands
& Hardcastle, 1983) whilst a sensitive test such as
Fecatest (Nordic Pharmaceuticals) has a false
positive rate which is unacceptably high when
subjects are on an unrestricted diet (Beretta et al.,
1978).
Immunological tests specific for human
haemoglobin should overcome both of these
problems as the sensitivity can be adjusted and
there is no cross reaction with animal haemoglobin
or vegetable peroxidase. Several such tests have
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been described, using different immunological
methods, such as radial immunodiffusion (Barrows
et al., 1978; Williams et al., 1982), immuno-
fluorescence (Vellacott et al., 1981) and an
enzyme-linked immunoassay (ELISA) (Turunen
et al., 1984).
The ELISA test has recently been combined with
a sensitive guaiac test, Fecatwin Sensitive/Feca EIA
(Turunen et al., 1984). This test has been used to
screen an asymptomatic population and compared
with Haemoccult, the guaiac test most extensively
used in screening studies for colorectal cancer
(Hardcastle et al., 1983, Farrands et al., 1981,
Winawer et al., 1980), the yield and workload
generated by both tests being investigated.
Patients and methods
Six thousand four hundred and fifty individuals
between the ages of 45-75 were identified from
general practitioners' records in three general
practices in the Nottingham area. Those with
known large bowel disease and those considered
unsuitable by the family doctor were excluded. The
remaining subjects were randomly allocated by
household to either test or control group.
The 3,225 test subjects were sent an explanatory
letter from their family doctor with instructions to
perform both Haemoccult and Fecatwin Sensitive
tests for 3 days. No dietary restrictions were
imposed. The completed kits were developed,
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without rehydration, with two drops of hydrogen
peroxide, any blue colour at 30 sec indicating a
positive test. In positive Fecatwin Sensitive guaiac
tests the appropriate filter discs were removed from
the "laboratory side" of the plastic container and
either tested immediately or stored at -20°C until
the next test - within one week. The discs were
placed into cuvettes pre-coated with antihuman
haemoglobin (Labsystems Corp, Helsinki), and the
haemoglobin was eluted from the filter disc by
phosphate buffer pH 7.4, and bound to the side of
the cuvette by the antihuman haemoglobin. After
washing, alkaline phosphatase conjugated antihuman
haemoglobin was added and incubated for 2h at
37°C. The cuvette was again washed and
paranitrophenyl phosphate, a substrate for alkaline
phosphatase, added. The reaction was terminated
with NaOH and the end product, paranitrophenyl,
proportional to the haemoglobin in the filter disc,
measured photometrically using an FP901
chemistry analyser (Labsystems). A positive result
was recorded when the mean absorbance of the test
disc, less the mean absorbance of a blank cuvette,
was >0.030.
Subjects with a positive Haemoccult test or
immunological Feca EIA test were seen and a full
history and examination performed including rigid
sigmoidoscopy and 60cm fibreoptic sigmoidoscopy.
Patients found to have a carcinoma in the left
colon had a double contrast barium enema before
surgery. Patients found to have adenomas were
colonoscoped and endoscopic polypectomy
performed. Individuals in whom no neoplasia was
detected had a double contrast barium enema, all
of which were performed by a single radiologist
(SSA). All cancers and adenomas were reviewed by
a single pathologist (PJ) accorded a Dukes' Stage
for cancers and histological type and degree of
dysplasia for adenomas. Subjects with negative
large bowel investigations were asked to repeat the
tests after appropriate dietary restrictions and, if
positive, gastroscoped.
Results
A total of 21 tests were made on different days
from new kits of two different batches. The
mean+s.d. for the blank and control values were
0.179+0.083 and 1.448+0.232 respectively. All
positive control values were in the positive range
and the mean+s.d. for each batch of kits is shown
in Table T. On one run the blank values were
unexpectedly high. The patients investigated on the
basis of this day's testing have been included since
one cancer was detected but the values are not
included in Table I.
The response and positivity rate for the tests can
Table I Mean blank and positive controls for Feca EIA
test
Mean absorbance
Positive
Batch no. No. ofkits Blank control
1. BD2 5 0.132+0.022 1.644+0.135
2. BD 2 15 0.195+0.091 1.383+0.22
Table II Number of individuals with positive faecal
occult blood text (%)
Haemoccult+Feca EIA positive 21
Haemoccult positive- Feca EIA negative 19 (3.1)
Fecatwin Sensitive (guaiac) positive 338 (25.8)
Fecatwin Sensitive/Feca EIA positive 106 (8.1)
Feca EIA positive - Haemoccult negative 86 (8.0)
be seen in Figure 1. Forty tests (3.1%) were
Haemoccult positive, with 106 (8.1%) Feca EIA
positive (Table TI).
Examination of the subjects with a positive test
yielded neoplastic disease in 32 individuals. Five
carcinomas were identified (3.8 per 1,000 persons
screened); 4 were Dukes' Stage A and one Dukes'
Stage C. Two of the carcinomas were situated in
the rectum and one in the sigmoid colon; two were
invasive carcinoma in sessile adenomas in the recto-
sigmoid. Thirty-seven adenomas were identified in
29 patients; four of these were greater in diameter
than 2cm, 19 between 1 and 2cm and 14 smaller
than 1 cm. Histology showed two to be villous
adenomas, 13 to be tubulo-villous and 18 to be
tubular (4 polyps were not retrieved at endoscopy).
The degree of cellular dysplasia was moderate in 15
and severe in 6.
The yields of Haemoccult, Fecatwin Sensitive and
Feca EIA tests for neoplastic disease are as shown
in Table TT and the breakdown of Haemoccult and
Feca EIA results are shown in Table IV.
All five carcinomas were Feca EIA positive, 2
were Haemoccult negative. The 4 adenomas >2cm
were Haemoccult positive whilst only 2 were Feca
EIA positive. All 6 adenomas showing severe
cellular dysplasia were Haemoccult positive, but
only 2 were Feca positive.
Four individuals with inflammatory bowel
disease were identified, 8 individuals with diverti-
cular disease, 10 with significant haemorrhoids and
2 with anal fissures. One patient with a positive
Feca EIA test had had a previous uretero-
sigmoidostomy for benign disease, which had been
revised to an ideal conduit. Colonoscopy wasFAECAL OCCULT BLOOD TESTS IN COLORECTAL CANCER SCREENING 801
Subjects enrolled
6,450
Test group Control group
1
3,22 3,225
Tests delivered GPO Returns
2,978 247
Tests completed Refused test No response
1,304
(43.8%)
Number positive
617
(20.7%)
1,057
(35.5%)
126
(9.7%)
Figure 1 Response of asymptomatic individuals offered faecal occult blood testing.
Table III Yield of neoplastic disease
Haemoccult + ve Fecatwin "S" +ve Feca EIA + ve Total
(%) (%) (%) Cancer 3 (60) 5 (100) 5 (100) 5
Adenomas:
>2cm 4 (100) 3 (75) 2 (50) 4
1-2cm 16 (84) 17 (89) 9 (47) 19
<1cm 5 (36) 12 (86) 11 (79) 14
28 (67) 37 (88) 27 (64) 42
unsatisfactory due to angulation of the colon and
barium enema showed a sessile polypoid lesion in
the sigmoid colon. Because of the risk of
malignancy a sigmoid colectomy was performed.
Histology revealed only a polypoid ureterosigmoid
anastomosis.
The findings and maximum absorbance values
for each patient are shown in Figure 2. For patients
with more than one adenoma, only the largest is
included in the figure.
In the Haemoccult positive subjects, 7 were
found to have a recognisable non-neoplastic cause
for bleeding and in only 9 was no cause for
bleeding found. In the Feca EIA positive subjects, a
non-neoplastic cause for bleeding was found in 24,
and 54 were found to have no cause for bleeding.Table IV Final diagnosis ofpatients with positive faecal occult blood tests
Haemoccult only Haemoccult +ve Feca EIA only
positive Feca EIA +ve positive
Neoplastic
Cancers 0 3 2
Adenomas: >2cm 2 2 0
1-2cm 10 6 3
<1cm 3 2 9
Non-neoplastic
disease:
Haemorrhoids 3 1 7
Inflammatory bowel disease 0 1 3
Diverticular disease 1 2 5
Anal fissure 0 0 2
Other 0 0 3
No cause for bleeding found 4 5 49
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Figure 2 Maximum absorbance of individuals investigated with positive faecal occult blood tests.
I.B.D.=Inflammatory Bowel Disease.
802
,,~ ~~~---- OLFAECAL OCCULT BLOOD TESTS IN COLORECTAL CANCER SCREENING 803
Sixty-five patients completed re-testing and only
two were positive of Feca EIA. In these individuals
upper gastrointestinal investigations were under-
taken. In one an early gastric carcinoma was
diagnosed; the other showed changes of gastric
metaplasia.
Eight individuals refused investigation and one
died between completing the tests and investigation.
Discussion
One thousand three hundred and four (44%) of
individuals completed and returned both screening
tests. Thus the addition of a second test does not
appear to reduce the acceptance of the screening
test when compared with Haemoccult alone (42%)
(Hardcastle et al., 1983). The detection rate for
colorectal cancers (3.8 per 1000 persons screened) is
similar to that found in a larger study in the
Nottingham area using Haemoccult (Hardcastle et
al., 1983). The detection rate for adenomas,
however, has been increased from 8.8 per 1000 to
17.6 per 1000 for adenomas >1 cm diameter.
If the tests are considered separately, then
Fecatwin Sensitive was the most sensitive, correctly
identifying all of the carcinomas and 20 of the 23
adenomas >1 cm diameter. However, the addition
of the Feca EIA component reduced the sensitivity
of the test and whilst all 5 cancers were detected,
only 11 (50%) of the adenomas >1 cm diameter
were detected. Haemoccult, on the other hand,
missed 2 cancers but detected 20 (87%) adenomas
> 1 cm diameter. It is well recognised that
Haemoccult has a false negative rate because
tumours bleed intermittently and the bleeding may
be slight (Macrae & St John 1982; Farrands &
Hardcastle, 1983), and the distribution in the stool
is not uniform. This can be reduced either by
rehydration of the samples (Macrae et al., 1982) or
by increasing the number of samples tested
(Farrands & Hardcastle, 1983). Equally, the use of
a more sensitive guaiac test such as Fecatwin
Sensitive will give a lower false negative rate but
higher false positive rate. Indeed, in this study the
overall positivity rate for Fecatwin "S" was over
25%. Many of the false positive results are the
result of crossreactions with animal haemoglobin or
vegetables peroxidases. The addition of the Feca
EIA component should, theoretically, eliminate
these false positives. However, a total of 61 (54%)
individuals were investigated and no cause for
bleeding was found. This may be due to minute
traces of haemoglobin in the stool or it may be due
to deterioration of the test discs on storage, even at
-20°C. Our own observations have indicated that
changes occur in the discs which "create" false
positive results (Armitage & Hardcastle, un-
published data).
It would be expected that a sensitive im-
munological test for haemoglobin should identify
all of the tumours which were Haemoccult positive.
This was, however, not the case. This might be due
to sampling error or since the immunological test
recognises the protein portion of haemoglobin it is
possible that the protein becomes changed by
bacterial action during transit through the bowel,
or during storage of the test discs. Frommer &
Kaparis (1983) found that haemoglobin concen-
trations in faeces smeared onto antibiotic treated
filter paper altered little over 28 days storage at
room temperature. Our own observations indicate
that, as well as the creation of false positives, there
is a marked decrease in haemoglobin activity if the
discs are stored at room temperature, which is less
if stored at -20°C (Armitage & Hardcastle,
unpublished data).
Thirty-seven individuals with a positive
Haemoccult test were investigated and neoplastic
disease detected in 21 (57%). However, only 21
(19.8%) of 106 individuals with a positive Feca
EIA test were found to have large bowel neoplasia.
A recognisable non-neoplastic cause for bleeding
was detected in 8 Haemoccult positive and 24 Feca
EIA positive subjects. The number of subjects in
whom no bleeding site could identified was only 9
for Haemoccult (24%) but 54 for Feca EIA (52%).
The large size of the latter group may be due partly
to unreliability of the test discs on storage or the
detection of minute amounts of haemoglobin
without recognisable cause, since all of the controls
for the assay itself appeared satisfactory.
This study has reproduced the detection rate for
colorectal cancer and the proportion of early
cancers found in the previously reported screening
study in the Nottingham area. Feca EIA has in-
creased the yield of neoplastic disease; however, the
high false positive rate makes the test in its present
form unsuitable for population screening.
As a result of the observations reported here and
studies performed on the reliability of the tests under
conditions of storage the manufacturers have modified the
test so that the "cut off" limit for positivity and the
stability on storage are improved.
The Fecatest Sensitive/Feca EIA reagent kits and
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